Anxiogenic-like activity of 3,4-methylenedioxy-methamphetamine ("Ecstasy") in the social interaction test is accompanied by an increase of c-fos expression in mice amygdala

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 2, 2004, Pages 249-254

  Navarro, José Francisco ^a   Rivera, Alicia ^a   Maldonado, Enrique ^a   Cavas, María ^a   De La Calle, Adelaida ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Amygdala; Anxiety; c fos; MDMA

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL MODEL; EXPERIMENTAL TEST; GENE EXPRESSION; IMMOBILIZATION; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; RECORDING; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE;

EID: 1642564046     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.10.016     Document Type: Article

References (35)

1. Bhattacharya S.K., Battacharya A., Ghosal S. Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy). An experimental study. Biog. Amines. 14:1998;217-237.
2. Braida D., Pozzi M., Cavallini R., Sala M. 3,4 Methylenedioxymethamphetamine (Ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats. Behav. Pharmacol. 116:2002;298-304.
3. Brain P.F., McAllister K.H., Walmsley S. Drug effects on social behavior: methods in ethopharmacology. Boulton A.A., Baker G.B., Greenshaw A.J. Neutomethods. 1989;687-739 Humana Press, Clifton, NJ.
4. Cole J.C., Sumnal H.R. Altered states: the clinical effects of Ecstasy. Pharmacol. Ther. 98:2003;35-58.
5. Cole J.C., Sumnal H.R. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev. 27:2003;199-217.
6. Curran T., Morgan J.I. Fos: an immediate-early transcription factor in neurons. J. Neurobiol. 26:1995;403-412.
7. Dragunow M., Logan B., Laverty R. 3,4-Methylenedioxymethamphetamine induces Fos-like proteins in rat basal ganglia: reversal with MK 801. Eur. J. Pharmacol. 206:1991;255-258.
8. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology. 161:2002;356-364.
9. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods. 2:1980;219-238.
10. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 463:2003;35-53.
11. Fletcher P.J., Korth K.M., Robinson S.R., Baker G.B. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology. 162:2002;282-291.
12. Gamma A., Frei E., Lehmann D., Pascual-Marqui R.D., Hell D., Vollenweider F.X. Mood state and brain electric activity in ecstasy users. NeuroReport. 11:2000;157-162.
13. Green A.R., McGregor I.S. On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology. 162:2002;448-450.
14. Gurtman C.G., Morley K.C., Li K.M., Hunt G.E., McGregor I.S. Increases anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur. J. Pharmacol. 446:2002;89-96.
15. Harlam R.E., García M.M. Drugs of abuse and immediate-early genes in he forebrain. Mol. Neurobiol. 16:1998;221-267.
16. Hashimoto K., Tomitaka S., Narita N., Minabe Y., Ino M. Induction of Fos protein by 3,4-methylenedioxymethamphetamine (Ecstasy) in rat brain: regional differences in pharmacological manipulation. Addict. Biol. 2:1997;317-326.
17. Hubner C., Bird M., Rassnick S., Kornetsky C. The threshold lowering effects of MDMA (Ecstasy) on brain-stimulation reward. Psychopharmacology. 95:1988;49-51.
18. Killcross S., Robbins T.W., Everitt B.J. Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature. 388:1997;377-380.
19. Lin H.Q., Burden P.M., Christie M.J., Johnston G.A. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol. Biochem. Behav. 62:1999;403-408.
20. Maldonado E., Navarro J.F. Effects of 3,4-methylenedyoxymethamphetamine (MDMA) on anxiety tested in the light-dark box. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 24:2000;463-472.
21. Maldonado E., Navarro J.F. MDMA ("Ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol. Res. 44:2001;27-31.
22. Marona-Lewicka D., Rhee G., Sprague J., Nichols D. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav. 53:1996;99-105.
23. Morley K.C., McGregor I.S. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") increases social interaction in rats. Eur. J. Pharmacol. 408:2000;41-49.
24. Navarro J.F., Maldonado E. Behavioral profile of 3,4-methylenedioxy- methamphetamine (MDMA) in agonistic encounters between male mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 23:1999;327-334.
25. Navarro J.F., Maldonado E. Acute and subchronic effects of MDMA ("Ecstasy") on anxiety in male mice tested in the elevated plus-maze. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;1151-1154.
26. Navarro J.F., Maldonado E. Effects of acute, subchronic and intermittent MDMA ("Ecstasy") administration on agonistic interactions between male mice. Aggress. Behav. 30:2004;. (in press).
27. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoact. Drugs. 18:1986;305-313.
28. Parrot A.C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology. 139:1998;261-268.
29. Parrot A.C., Sisk E., Turner J.D. Psychobiological problems in heavy "Ecstasy" (MDMA) polydrug users. Drug Alcohol Depend. 60:2000;105-110.
30. Sajdyk T.J., Shekhar A. Sodium lactate elicits anxiety in rats after repeated GABA receptor blockade in the basolateral amygdala. Eur. J. Pharmacol. 394:2000;265-273.
31. Singewald N., Salchner P., Sharp T. Induction of c-fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry. 53:2003;275-283.
32. Soar K., Turner J.J., Parrott A.C. Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum. Psychopharmacol. Clin. Exp. 16:2001;641-645.
33. Stephenson C.P., Hunt G.E., Topple A.N., McGregor I.S. The distribution of 3,4-methylenedioxymethamphetamine-induced c-fos expression in rat brain. Neuroscience. 92:1999;1011-1023.
34. Walker D.L., Toufexis D.J., Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur. J. Pharmacol. 463:2003;199-216.
35. Winslow J.T., Insel T.R. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 254:1990;212-220.